We are live on ! Find out more
CELGZ

Celgene Corporation Contingent Value Rights

Delisted

CELGZ was delisted on the 29th of November, 2019.

21 hedge funds and large institutions have $1.29M invested in Celgene Corporation Contingent Value Rights in 2017 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 3 increasing their positions, 5 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

4% more capital invested

Capital invested by funds: $1.25M → $1.29M (+$46.7K)

5% less funds holding

Funds holding: 2221 (-1)

40% less repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 5

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 1

Holders
21
Holders Change
-1
Holders Change %
-4.55%
% of All Funds
0.52%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
Increased
3
Reduced
5
Closed
1
Calls
Puts
Net Calls
Net Calls Change

CELGZ Hedge Fund Activity: Q2 2017 in Review

21 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Celgene Corporation Contingent Value Rights (CELGZ) for Q2 2017, worth a combined $1.29M — up 3.7% from $1.25M a quarter earlier.

Sellers outnumbered buyers: 1 fund closed out of CELGZ and 0 opened new positions — a net loss of 1 holder — while 5 trimmed existing stakes and 3 added.

The largest buyer was Davenport & Co, adding an estimated $12.3K. The largest seller was United Asset Strategies, exiting entirely with an estimated $121K sold.

  • 21 institutional investors held Celgene Corporation Contingent Value Rights (CELGZ) as of Q2 2017, down from 22 in Q1 2017.
  • Funds reported $1.29M of Celgene Corporation Contingent Value Rights stock for Q2 2017, up 3.7% quarter-over-quarter.
  • 0 funds opened new Celgene Corporation Contingent Value Rights positions in Q2 2017 and 1 closed out, a net change of -1 holder.
  • The largest Celgene Corporation Contingent Value Rights buyer in Q2 2017 was Davenport & Co, an estimated $12.3K added.
  • The largest Celgene Corporation Contingent Value Rights seller in Q2 2017 was United Asset Strategies, an estimated $121K sold.

Based on aggregated 13F filings for Q2 2017.